Combination Therapies for Melanoma: A New Standard of Care?
- 10 February 2016
- journal article
- research article
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 17 (2) , 99-105
Abstract
Recent data have demonstrated improved survival with targeted and immune therapies in patients with advanced melanoma, leading to much excitement amongst the oncology community and the widespread use of these drugs in combination regimens. However, the place of these combination therapies in the treatment of advanced melanoma remains to be fully determined. In this perspectives article, we critically review the available data and outline the rationale for these combinations being adopted as the standard of care for patients with advanced melanoma in the future.Keywords
Funding Information
- National Cancer Institute (CA168536, CA161107, R21 CA198550)
This publication has 42 references indexed in Scilit:
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK InhibitionCancer Discovery, 2014
- Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanomaNature Reviews Clinical Oncology, 2013
- Targeting Oncogenic Drivers and the Immune System in MelanomaJournal of Clinical Oncology, 2013
- Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaNew England Journal of Medicine, 2012
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences, 2008
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II TrialsJournal of Clinical Oncology, 2008
- Mutations of the BRAF gene in human cancerNature, 2002